Previous 10 | Next 10 |
2023-08-29 09:32:01 ET More on Evaxion Biotech ADS Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst Evaxion Biotech ADS GAAP EPS of -$0.21 misses by $0.01 Evaxion stock slumps ~10% despite developing AI tool for cancer therapy Evaxio...
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced: Evaxion has hired a new Ch...
2023-08-22 17:34:06 ET Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023, 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Confer...
2023-08-18 13:35:12 ET More on Evaxion Biotech ADS Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst Evaxion stock slumps ~10% despite developing AI tool for cancer therapy Evaxion stock surges ~25% on preclinical data for mRNA vaccine for ca...
Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023 A novel proprietary genetic vaccine adjuvant was presented at Evaxion’s R&D Day in May. The technology is an integral part of the next-generation cancer vaccine, EV...
2023-08-02 15:58:47 ET Summary Interim results from the phase 2 study, using EVX-01 for the treatment of patients with metastatic melanoma, is expected in Q4 of 2023. Positive preliminary results have already been established in using EVX-01 for metastatic melanoma patients and EV...
2023-08-01 18:00:01 ET Evaxion Biotech ( EVAX ) has entered into a binding agreement for a financing of up to US$20 million with Negma Group, the company said Tuesday. The company can avail financing in tranches of up to US$700,000 over a period of 36 months. The fin...
Financing, available in multiple tranches over the next three years, could extend the Company’s runway into Q4 2024 Transaction will enable Evaxion to advance its next-generation cancer vaccine, EVX-03, towards a Phase 1 clinical trial Copenhagen, DENMARK, Aug. 01, 2023 (GLOBE NE...
EVX-B1, a vaccine against Staphylococcus aureus (S. aureus) containing AI-identified antigens, is highly protective against S. aureus disease in preclinical animal models EVX-B1 immunization resulted in complete bacterial clearance of S. aureus in multiple organs COPENHAGEN,...
2023-06-06 08:19:00 ET HTG Molecular Diagnostics ( HTGM ) -40% . Ucommune International ( UK ) -16% . EZGO Technologies EZGO -8% on $8.5M direct offering . Timber Pharmaceuticals ( TMBR ) -10% . Celestica CLS -8% on pricing secondary sto...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...